Inhaled siRNA therapy has a unique potential for treatment of severe lung diseases, such as
cystic fibrosis (CF). Nevertheless, a drug delivery system tackling lung barriers is mandatory …

The pulmonary delivery of drugs is the most striking target and of incredible scientific and
biomedical attention in the research of health care because the lung is able to absorb …

Many pathologies of the respiratory tract are inadequately treated with existing small
molecule-based therapies. The emergence of RNA interference (RNAi) enables the post …

Pulmonary delivery of anti-inflammatory siRNA presents a promising approach for localized
therapy of acute lung injury (ALI), while polycationic vectors can be easily trapped by the …

This study describes the physicobiological characterization of PEI− and PEG− PEI
polyplexes containing partially 2′-OMe modified 25/27mer dicer substrate siRNAs …

RNA interfering technology has become a successful strategy for targeted gene silencing
through the use of efficient delivery systems. A nanocarrier must be especially designed …

The regulation of genes utilizing the RNA interference (RNAi) mechanism via the delivery of
synthetic siRNA has great potential in the treatment of a variety of lung diseases. However …

Small interfering RNA (siRNA)-based therapies have great promise in the treatment of a
number of prevalent pulmonary disorders including lung cancer, asthma and cystic fibrosis …

RNA interference (RNAi) may provide a therapeutic solution to many pulmonary epithelium
diseases. However, the main barrier to the clinical use of RNAi remains the lack of efficient …

The mucus layer and cell membrane are two major barriers against pulmonary siRNA
delivery. Commonly used polycationic gene vectors can hardly penetrate the mucus layer …